Swiss pharmaceutical giant Novartis has announced the sale of its entire 70.68% stake in its listed Indian subsidiary for approximately ₹1,446 crore to a consortium led by ChrysCapital. According to The Economic Times, this divestment aligns with Novartis' strategy to become a pure-play innovative medicines company, while the parent company retains a significant presence in India through its wholly owned subsidiary. The deal involves ChrysCapital, WaveRise Investments, and Two Infinity Partners, with the parent company retaining its 70.7% shareholding through this transaction.
The divestment represents a strategic shift as Novartis focuses on high-value, innovation-led medicines while exiting its legacy portfolio. As reported by The Times of India, the company has been conducting a two-year strategic review of its Indian operations, including assessing its stake in the Mumbai-based firm. After the deal completion, Novartis will retain its unlisted entity Novartis Healthcare, which houses its high-value innovative medicines portfolio. This restructuring allows the company to concentrate on its core strengths while maintaining a substantial presence in the Indian pharmaceutical market.
The market responded positively to the announcement, with Novartis India shares closing 20% higher at ₹997 on BSE on Friday. According to The Times of India, the parent company has also announced a mandatory open offer to acquire an additional 26% stake at ₹861 per share, demonstrating confidence in the valuation of the Indian operations. The ₹1,446 crore transaction reflects the market's confidence in Novartis' strategic pivot and the value of its Indian operations.
Following the completion of this transaction, Novartis will expand its portfolio in India to include cardio, renal, metabolic, and oncology medicines. As reported by The Times of India, the company's global CEO Vas Narasimhan reaffirmed at Davos 2025 that the divestment remains on track while underscoring Novartis' commitment to India's long-term potential in the pharmaceutical sector. This strategic move positions Novartis to focus on higher-value therapeutic areas while maintaining its strong market position in the Indian pharmaceutical landscape.
